research Enhanced skin permeation of 5α-reductase inhibitors entrapped into surface-modified liquid crystalline nanoparticles
Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.
Search
for
Sort by
Research
960-990 / 1000+ results 
research Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway
DA-9401 helps protect rat testis from finasteride damage.
research Interconnected PolymerS TeChnology (IPSTiC): An Effective Approach for the Modulation of 5α-Reductase Activity in Hair Loss Conditions
A new anti-baldness patch effectively treats hair loss by blocking enzymes linked to the condition.
research SAT-279 The Effect of Chronic 5-alpha Reductase Inhibition on Clinically Apparent and Silent Cardiovascular Events
Finasteride lowers cholesterol but doesn't reduce heart-related events.
research Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition
Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
research An Antifungal for Antidiuresis?
Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
research Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research CAN PATIENTS WITH LUTS AND BPH DISCERN CHANGES IN PEAK URINARY FLOW RATE AND DO SUCH CHANGES CONTRIBUTE TO OVERALL SATISFACTION WITH TREATMENT?
Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
research 5α-Reductases in Human Physiology: An Unfolding Story
Enzymes called 5α-reductases have many body functions and need more research to safely use inhibitors.
research Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system
The new saw palmetto extract effectively inhibits an enzyme linked to prostate enlargement and may be as good as standard treatments.
research Synthesis and Pharmacological Evaluation of New 16-Methyl Pregnane Derivatives.
New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
research Physicochemical characterization of finasteride:PEG 6000 and finasteride:Kollidon K25 solid dispersions, and finasteride: β-cyclodextrin inclusion complexes
Finasteride's solubility and bioavailability improved by forming solid dispersions and inclusion complexes.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
Finasteride safely lowers DHT levels without affecting testosterone.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Pharmacological Activity and Clinical Use of PDRN
PDRN helps repair tissue and improve wound healing with a high safety profile.
research Post-finasteride syndrome
Finasteride may cause lasting sexual, mental, and physical symptoms; use with caution.
research Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.
research Improvement of Techniques of Synthesis of Finasteride
The new method for making Finasteride is cheaper and safer for large-scale production.
research 5α‐reductase inhibitors: Evaluation of their potential confounding effect on GC‐C‐IRMS doping analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.